Data collected by Liang et al. and analyzed by Hale et al., shows that CD36 expression at mRNA and protein levels correlates with poor prognosis of GBM patients, pointing CD36 as a prognosis biomarker for patient survival (Liang et al., 2005; Hale et al., 2014). This evidence concerns the gene CD36 and glioblastoma.